NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

Fintech startup Kiwi, which pioneered the concept of Credit-on-UPI, has raised $24 million (Rs 208 crore) in its Series B funding round led by Vertex Ventures South East Asia & India, with ...

Disappointing trial results for VX-993 led to a sell-off of Vertex's stock recently. The company's financials remain strong, and sales were up 12% last quarter. Vertex has been broadening its pipeline ...

According to draft papers, the OFS ( offer for sale) comprises shares held by Vertex Ventures, Ventureast, Endiya Seed and Aion Advisory Services. As per Tracxn, Vertex holds 24% in Kissht, Ventureast ...

Vertex Inc. reported its second-quarter earnings for 2025, showcasing a modest earnings beat with an EPS of $0.15 compared to the forecasted $0.14. The revenue aligned with expectations at $184.6 ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Vertex Pharmaceuticals made its name and fortune by ...

Vertex Pharmaceuticals’VRTX-0.26%decrease; red down pointing triangle stock fell in post-market trading Monday, after the company said it would not progress a next-generation pain treatment into ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled ...

Vertex Pharmaceuticals (VRTX) recently reported a slight gain of 0.16% as of the close on July 30, 2025, amidst fluctuating market conditions. The company’s trading volume of $470 million positions it ...